GLP-1 & Weight Management

Tirzepatide

Tirzepatide — research-grade reference material, supplied in multiple sizes.

Product Code: TRZ
Purity: 99%
Form: Lyophilized powder
Packaging: 1 box / 10 vial

Ships from multiple warehouses — typically 2–5 business days to nearby destinations. International orders coordinated per destination.

No prices are published. Available scope, specifications and documentation are confirmed during specification review. Supplied for research and analytical use by qualified organizations — see our Research Use Only policy.

Specification

Purity specification: 99%
Appearance: White to off-white lyophilized powder
Solubility: Reconstitutes in sterile or bacteriostatic water
Counter ion: Acetate
Form: Lyophilized Powder
Available sizes: 2mg × 10vials, 5mg × 10vials, 10mg × 10vials, 15mg × 10vials, 20mg × 10vials, 30mg × 10vials, 40mg × 10vials, 50mg × 10vials, 60mg × 10vials, 80mg × 10vials, 100mg × 10vials
Storage: Store lyophilized powder at −20°C in a sealed container, protected from light and moisture. Stable for 24+ months unreconstituted. After reconstitution, keep refrigerated and use within the working window noted on the report. Allow the vial to reach room temperature before opening.
MOQ: On request

Research Applications

Research use: tirzepatide, a GIP/GLP-1 receptor co-agonist, is used to study the metabolic synergy of dual incretin receptor activation.
Weight-loss research (SURMOUNT program) examines its superior fat-mass reduction versus GLP-1 mono-agonists.
Used in glycemic-metabolism studies to investigate GIPR-dependent insulinotropic and adipocyte signaling.
Serves as a reference compound in comparative pharmacology of incretin co-agonists for T2D and metabolic.

Dual target GIP/GLP-1 agonist, metabolic-research effect studied for metabolic applications (SURMOUNT research series)